{"id":"NCT03088267","sponsor":"Tris Pharma, Inc.","briefTitle":"Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study","officialTitle":"Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children Wit","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-11","primaryCompletion":"2017-02-25","completion":"2017-10-30","firstPosted":"2017-03-23","resultsPosted":"2019-07-09","lastUpdate":"2019-07-22"},"enrollment":18,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"amphetamine extended-release oral suspension, 2.5 mg/mL","otherNames":["Dyanavel XR"]},{"type":"DRUG","name":"Placebo extended-release oral suspension","otherNames":[]}],"arms":[{"label":"Active Treatment","type":"ACTIVE_COMPARATOR"},{"label":"Placebo Treatment","type":"PLACEBO_COMPARATOR"}],"summary":"This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12 years.","primaryOutcome":{"measure":"Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose","timeFrame":"Change in SKAMP-C score from baseline to 30 minutes postdose.","effectByArm":[{"arm":"Active Treatment","deltaMin":-6.1,"sd":2.29},{"arm":"Placebo Treatment","deltaMin":2.5,"sd":2.29}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0118"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["30575407"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Upper respiratory tract infection","Fatigue","Abdominal pain, upper","Headache","Decreased appetite"]}}